Rutaecarpine alleviates inflammation and fibrosis by targeting CK2α in diabetic nephropathy

Biomed Pharmacother. 2024 Nov:180:117499. doi: 10.1016/j.biopha.2024.117499. Epub 2024 Sep 30.

Abstract

Diabetic nephropathy (DN) is one of the serious microvascular complications of diabetes mellitus. During the progression of DN, the proliferation of glomerular mesangial cells (GMCs) leads to the deposition of excessive extracellular matrix (ECM) in the mesangial region, eventually resulting in glomerulosclerosis. Rutaecarpine (Rut), an alkaloid found in the traditional Chinese medicinal herb Fructus Evodiae (Euodia rutaecarpa (Juss.) Benth.), has many biological activities. However, its mechanism of action in DN remains unknown. This study used db/db mice and high glucose (HG)-treated mouse mesangial cells (SV40 MES-13) to evaluate the protective effects of Rut and underlying mechanisms on GMCs in DN. We found that Rut alleviated urinary albumin and renal function and significantly relieved renal pathological damage. In addition, Rut decreased the ECM production, and renal inflammation and suppressed the activation of TGF-β1/Smad3 and NF-κB signaling pathways in vitro and in vivo. Protein kinase CK2α (CK2α) was identified as the target of Rut by target prediction, molecular docking, and cellular thermal shift assay (CETSA), and surface plasmon resonance (SPR). Furthermore, Rut could not continue to play a protective role in HG-treated SV40 cells after silencing CK2α. In summary, this study is the first to find that Rut can suppress ECM production and inflammation in HG-treated SV40 cells by inhibiting the activation of TGF-β1/Smad3 and NF-κB signaling pathways and targeting CK2α. Thus, Rut can potentially become a novel treatment option for DN.

Keywords: Diabetic nephropathy; Glomerular mesangial cells; NF-κB; Protein kinase CK2α; Rutaecarpine; TGF-β1/Smad3.

MeSH terms

  • Animals
  • Casein Kinase II* / antagonists & inhibitors
  • Casein Kinase II* / metabolism
  • Cell Line
  • Diabetic Nephropathies* / drug therapy
  • Diabetic Nephropathies* / metabolism
  • Diabetic Nephropathies* / pathology
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / metabolism
  • Fibrosis* / drug therapy
  • Indole Alkaloids* / pharmacology
  • Inflammation / drug therapy
  • Inflammation / pathology
  • Male
  • Mesangial Cells / drug effects
  • Mesangial Cells / metabolism
  • Mesangial Cells / pathology
  • Mice
  • Mice, Inbred C57BL
  • Molecular Docking Simulation
  • NF-kappa B / metabolism
  • Quinazolines* / pharmacology
  • Quinazolines* / therapeutic use
  • Quinazolinones
  • Signal Transduction / drug effects
  • Smad3 Protein / metabolism
  • Transforming Growth Factor beta1* / metabolism

Substances

  • rutecarpine
  • Indole Alkaloids
  • Casein Kinase II
  • Quinazolines
  • Transforming Growth Factor beta1
  • NF-kappa B
  • Smad3 Protein
  • Quinazolinones